DE10199068I1 - Sublinguale Dosierungsformen enthaltend Apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion - Google Patents

Sublinguale Dosierungsformen enthaltend Apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion

Info

Publication number
DE10199068I1
DE10199068I1 DE2001199068 DE10199068C DE10199068I1 DE 10199068 I1 DE10199068 I1 DE 10199068I1 DE 2001199068 DE2001199068 DE 2001199068 DE 10199068 C DE10199068 C DE 10199068C DE 10199068 I1 DE10199068 I1 DE 10199068I1
Authority
DE
Germany
Prior art keywords
treatment
dosage forms
erectile dysfunction
forms containing
sublingual dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2001199068
Other languages
English (en)
Other versions
DE10199068I2 (de
Inventor
El-Rashidy Ragab
Heaton Jeremy
Morales Alvaro
Adams Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Pentech Pharmaceuticals Inc
Original Assignee
Queens University at Kingston
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10199068(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Queens University at Kingston, Pentech Pharmaceuticals Inc filed Critical Queens University at Kingston
Publication of DE10199068I1 publication Critical patent/DE10199068I1/de
Application granted granted Critical
Publication of DE10199068I2 publication Critical patent/DE10199068I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
DE2001199068 1994-04-22 1995-04-21 Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion. Active DE10199068I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22
PCT/US1995/004897 WO1995028930A1 (en) 1994-04-22 1995-04-21 Dosage forms and method for ameliorating male erectile dysfunction

Publications (2)

Publication Number Publication Date
DE10199068I1 true DE10199068I1 (de) 2003-06-05
DE10199068I2 DE10199068I2 (de) 2004-05-06

Family

ID=22868404

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69514794T Expired - Lifetime DE69514794T2 (de) 1994-04-22 1995-04-21 Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
DE69534693T Expired - Fee Related DE69534693T2 (de) 1994-04-22 1995-04-21 Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
DE2001199068 Active DE10199068I2 (de) 1994-04-22 1995-04-21 Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69514794T Expired - Lifetime DE69514794T2 (de) 1994-04-22 1995-04-21 Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
DE69534693T Expired - Fee Related DE69534693T2 (de) 1994-04-22 1995-04-21 Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz

Country Status (16)

Country Link
US (3) US5770606A (de)
EP (2) EP0758895B1 (de)
JP (1) JP3310982B2 (de)
KR (1) KR100374924B1 (de)
AT (2) ATE312609T1 (de)
AU (1) AU703608B2 (de)
CA (1) CA2188385C (de)
DE (3) DE69514794T2 (de)
DK (2) DK0978282T3 (de)
ES (2) ES2256999T3 (de)
GR (1) GR3033084T3 (de)
HK (2) HK1025742A1 (de)
LU (1) LU90856I2 (de)
NL (1) NL300072I1 (de)
PT (1) PT758895E (de)
WO (1) WO1995028930A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (de) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmische Zubereitung zur Behandlung von Kurzsichtigkeit enthaltend einen Dopaminagonisten und Cyclodextrin
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
AU749703B2 (en) * 1997-05-19 2002-07-04 Repros Therapeutics Inc. Combination therapy for modulating the human sexual response
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
KR20010021625A (ko) 1997-07-09 2001-03-15 추후보정 개선된 남성발기 기능장애 치료방법 및 그 조성물
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
AU5403499A (en) * 1998-08-26 2000-03-21 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US7718705B1 (en) * 1999-09-03 2010-05-18 Eli Lilly And Company Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CA2405419A1 (en) 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
HUP0302436A3 (en) 2000-11-15 2004-10-28 Tap Pharmaceutical Prod Inc Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (de) * 2001-01-19 2002-07-24 Sanofi-Synthelabo Neue Kombination mit Alfuzosin und Apomorphin als Aktiva
BR0207024A (pt) * 2001-02-08 2004-02-25 Pharmacia Corp Global Patent D Medicamento com ação inicial rápida para o tratamento de disfunção sexual
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
ES2271542T3 (es) * 2002-02-07 2007-04-16 Pharmacia Corporation Forma de dosificacion farmaceutica para administracion por la mucosa.
CN1720054A (zh) * 2002-03-19 2006-01-11 布雷恩及比扬德生物科技公司 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
JP4668611B2 (ja) * 2002-05-31 2011-04-13 タイタン ファーマシューティカルズ インコーポレイテッド ブプレノルフィンの持続放出のための埋め込み型ポリマー製装置
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
JP5064794B2 (ja) * 2003-03-31 2012-10-31 タイタン ファーマシューティカルズ インコーポレイテッド ドパミンアゴニストの徐放のための移植可能なポリマーデバイス
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AU2004281257C1 (en) * 2003-06-17 2010-07-01 Janssen Pharmaceutica N.V. Substituted spirobenzazepines
EA012754B1 (ru) 2005-10-12 2009-12-30 Юнимед Фармасьютикалз Ллк Усовершенствованный тестостероновый гель и способ его применения
JP2009523806A (ja) * 2006-01-20 2009-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
EA025054B1 (ru) 2009-06-12 2016-11-30 Сайнэпсус Терапьютикс, Инк. Единичная дозированная форма для сублингвального введения, включающая частицы апоморфина, для лечения болезни паркинсона или половой дисфункции
PL2651357T3 (pl) 2010-12-16 2020-08-24 Sunovion Pharmaceuticals Inc. Filmy podjęzykowe
JP2016535794A (ja) * 2013-11-11 2016-11-17 インパックス ラボラトリーズ，インコーポレーテッド 急速崩壊性製剤及びその使用法
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
EP0865789B1 (de) * 1993-03-26 2005-03-16 Franciscus Wilhelmus Henricus Maria Merkus Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin

Also Published As

Publication number Publication date
LU90856I2 (fr) 2002-01-24
JP3310982B2 (ja) 2002-08-05
US5770606A (en) 1998-06-23
US6200983B1 (en) 2001-03-13
WO1995028930A1 (en) 1995-11-02
ATE189121T1 (de) 2000-02-15
CA2188385C (en) 2000-07-11
EP0978282A3 (de) 2000-06-07
DE69534693D1 (de) 2006-01-19
AU703608B2 (en) 1999-03-25
DE69514794T2 (de) 2000-07-27
DE69514794D1 (de) 2000-03-02
ATE312609T1 (de) 2005-12-15
GR3033084T3 (en) 2000-08-31
ES2143049T3 (es) 2000-05-01
DK0758895T3 (da) 2000-06-13
US5985889A (en) 1999-11-16
EP0758895A1 (de) 1997-02-26
PT758895E (pt) 2000-05-31
DE10199068I2 (de) 2004-05-06
HK1014239A1 (en) 1999-09-24
DK0978282T3 (da) 2006-04-10
NL300072I1 (nl) 2002-02-01
EP0978282A2 (de) 2000-02-09
AU2295895A (en) 1995-11-16
KR970702041A (ko) 1997-05-13
KR100374924B1 (ko) 2003-07-22
HK1025742A1 (en) 2000-11-24
DE69534693T2 (de) 2006-08-31
EP0758895B1 (de) 2000-01-26
JPH09512273A (ja) 1997-12-09
EP0978282B1 (de) 2005-12-14
ES2256999T3 (es) 2006-07-16
EP0758895A4 (de) 1997-04-09
CA2188385A1 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
DE10199068I1 (de) Sublinguale Dosierungsformen enthaltend Apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion
ATE245650T1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
DE69319551D1 (de) Indolin Verbindungen zur Behandlung von Dysurien
ATE192151T1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE3882775T2 (de) Zusammensetzung zur Behandlung von parodontaler Krankheit.
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
NO903148L (no) Hemoreguleringspeptider.
DE69010294T2 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69302799T2 (de) Zusammensetzung für die Behandlung von Kesselwasser
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
DE3762526D1 (de) Hochkonzentrierte saeurezusammensetzungen fuer die behandlung von wasser und die reinigung von anlagen.
DE69504717T2 (de) Behandlung von organischen Verbindungen zur Reduzierung des Chlorgehaltes
ATE81972T1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
DE69214647D1 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
DE69103294D1 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
TR200000266T2 (tr) Antimetastaz maddeler olarak faydalı oligo-tiofenler, bunların ve bunları ihtiva eden farmasötik bileşimlerin hazırlanması.
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции
ATE225664T1 (de) Verwendung von humanem alpha 1-sauren glycoprotein zur herstellung einer pharmazeutischen präparation
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate
ATE64683T1 (de) Zusammensetzung zur behandlung von haemorroiden.
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
SU1533391A1 (ru) Состав для обработки призабойной зоны скважины